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ABSTRACT 
Recent scientific advances mean the widespread introduction of non-invasive prenatal diagnosis 
(NIPD) for chromosomal aneuploidies may be close at hand, raising the question of how NIPD should 
be introduced as part of antenatal care pathways for pregnant women. In this paper we examine the 
ethical implications of three hypothetical models for using NIPD for aneuploidy in state-funded 
healthcare systems and assess which model is ethically preferable. In comparing the models we 
consider their respective timings; how each model would fit with current screening and diagnostic 
tests offered to pregnant women; the implications of offering NIPD at different stages of pregnancy; 
and the potential for each model to support reproductive autonomy and informed decision-making. 
We conclude by favouring a model that would be offered at 11-13 weeks gestation, alongside 
existing combined screening, provided that this is accompanied by measures to maximise informed 
decision-making, for example provision of adequate pre- and post-test counselling. 
Key words: Genetic Screening/Testing, Genetic Counselling/Prenatal Diagnosis; ethics; aneuploidy; 
Down syndrome. 
 
INTRODUCTION 
Non-invasive prenatal diagnosis (NIPD) is a type of prenatal testing that promises early and 
potentially definitive results relating to aneuploidy and genetic conditions in pregnancy by testing 
fetal DNA present in maternal blood.[1] The test involves analysis of cell free fetal DNA (cffDNA) 
present in maternal blood, thus avoiding the risk of miscarriage that accompanies current invasive 
methods of prenatal diagnosis. There is particular interest in using NIPD to detect aneuploidies such 
as Down syndrome (Trisomy 21) or the rarer conditions Patau syndrome (Trisomy 13) and Edwards 
syndrome (Trisomy 18). As prenatal testing using non-invasive methods develops further, the 
question of how it should be implemented in clinical practice and antenatal screening is surfacing.[2-
4] 
NIPD technology is developing quickly, but recent validation studies have shown that NIPD is not yet 
fully accurate, only highly predictive, and that there is still a low false positive rate.[5-7] In view of 
this, the results from NIPD should be verified by invasive testing, and so for the time being it can 
only be regarded as an advanced screening test.[8] For the purposes of this paper we are assuming 
that NIPD is 100% accurate with no false positives, and that from 10 weeks gestation it will be 
capable of diagnosing Trisomies 13, 18 and 21. 
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Debate is ongoing as to how NIPD for aneuploidy should be implemented.[9] In this paper we 
consider three hypothetical models for implementing NIPD for aneuploidy in the context of a state-
funded screening programme where combined screening is currently offered. Model One involves 
offering NIPD at around 10 weeks, accompanied by an ultrasound scan to date the pregnancy but 
does not include any other components of the combined screening test; Model Two involves 
offering NIPD at 11-13 weeks gestation alongside the combined screening test. Model Three involves 
offering NIPD, instead of invasive testing, to women in whom the combined test predicts a high risk 
of Down syndrome. The main practical differences between these models are in the timing, and how 
they would fit into the antenatal care pathway, as such they would significantly impact on how and 
in what context women would be offered NIPD. 
We make a case for favouring Model Two, which varies from current practice by offering risk-free 
definitive information to all pregnant women, not just those whose fetuses are deemed to be at high 
risk of having a chromosomal abnormality. This model would mitigate concerns over inconvenient, 
extra ultrasounds and burdensome choices in Model One, and the false reassurance and limited 
access afforded by Model Three. However we also recognise the potential for Model Two to 
diminish informed decision-making through routinisation of prenatal testing subsequent to a 
possible loss of time to reflect. We suggest that these concerns could be overcome by well-
implemented counselling and claim that the wider accessibility of definitive information to all 
pregnant women is important.1 
SCIENTIFIC AND CLINICAL ASPECTS OF NIPD 
Many countries offer prenatal screening programmes for aneuploidy, most commonly during the 
second trimester, though increasingly in the first. For the purposes of this paper, we limit our 
discussion to offering NIPD within a state funded system where combined screening at 11-13 weeks 
followed by diagnostic invasive testing for pregnancies found to be at high-risk is currently offered. 
Combined screening incorporates the results of an ultrasound to measure nuchal translucency and a 
maternal blood test measuring biochemical markers to indicate the probability of the fetus being 
born with an aneuploidy. Women who receive a ‘high risk’ result are then offered invasive diagnostic 
testing, such as amniocentesis, which carries a small but significant risk of miscarriage (around 
1%).[10]  
One of the main advantages of NIPD is that it may be able to offer a definitive result without the 
miscarriage risk associated with current invasive testing. This offers a solution to the problem of 
women having to either settle for a probabilistic indication of aneuploidy, or putting their 
pregnancies at risk for definitive information. NIPD is based on the analysis of fragments of fetal DNA 
circulating in the pregnant woman’s blood. One method of analysis involves detecting a higher 
amount of the chromosome of interest (such as 21, 18 or 13) in maternal blood through the use of 
massively parallel sequencing (also known as next generation sequencing). Research into NIPD for 
aneuploidies is ongoing and several large validation studies have been conducted using this 
sequencing approach.2[5, 11] Indeed, NIPD is already commercially available in the United 
States,[12] but it should be noted that this non-invasive test for aneuploidy is not yet considered to 
be fully diagnostic and a positive result must be confirmed by invasive testing.[8] 
                                                          
1 Financial costs are essential for determining the ethical acceptability any model, since state-funded 
healthcare budgets are limited and resources should be allocated fairly. However, an economic 
analysis is beyond the scope of this paper. 
2 
For example, positive predictive values for NIPD for Down syndrome are 98.6% for high-risk women. However 
full karytoping (visual examination of all chromosomes) remains the “gold standard” for aneuploidy 
diagnosis.[7] 
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These developments are significant. Offering NIPD for aneuploidies may have important implications 
for the care of pregnant women and the choices they make. While current combined screening is 
safe, the initial set of results are probabilistic and require follow-up invasive testing for a definitive 
result. Invasive testing is, with the exception of rare technical problems, definitive but women face a 
small risk of miscarriage to determine whether her fetus has an aneuploidy. With NIPD, women 
could potentially choose to receive definitive information about aneuploidies earlier, without the 
risk of loosing the pregnancy. Assuming there is good justification to introduce NIPD for detection of 
aneuploidies, an important question is how best to implement it in state-funded antenatal care 
pathways. 
It is important to note that in the area of prenatal testing it is not only NIPD that is making rapid 
advances; other technologies are allowing the range of prenatal testing options to expand. 
Consequently other developments for NIPD and for prenatal testing in general may eventually 
supersede the models proposed here and challenge the ethical framework in which prenatal testing 
is based.[13] 
POSSIBLE MODELS OF NIPD 
Models for implementing NIPD for aneuploidy have already been suggested in the literature.[4] Here 
we formulate and discuss three hypothetical models. We recognise that how NIPD will be 
implemented depends on technological and economic considerations, but we have chosen these 
models because we believe them to be practically and clinically feasible in a state-funded antenatal 
care pathway. All are based on the assumption that NIPD is 100% accurate with no false negatives, 
reliable from 10 weeks gestation and can only detect Trisomies 13, 18 and 21.  
Model One: Instead of combined screening, NIPD would be offered to all pregnant women, 
regardless of age, and would be carried out following a dating scan at around 10 weeks 
gestation.  
Model Two: NIPD would be offered to all pregnant women regardless of age and would be 
carried out at 11-13 weeks gestation alongside the current combined test. Since we are 
assuming 100% accuracy for the purposes of this evaluation, there would be no need for 
further invasive tests for confirmation of Trisomies 13, 18, 21. 
Model Three: Combined screening, which gives a probabilistic result, would still be carried 
out for chromosomal aneuploidies at 11-13 weeks gestation as it is now, and would be 
offered to all pregnant women regardless of age. For those women found to be at ‘high risk’ 
NIPD would be offered instead of invasive testing. 
Model One 
The most significant features of Model One are that the information about aneuploidies obtained 
through a screening programme would be definitive (rather than probabilistic, followed by invasive 
diagnosis, as with current testing), and would be received in the first trimester. This model would 
mean that every woman attending early enough for antenatal care (not just those deemed high risk) 
would be offered definitive information about whether her fetus had an aneuploidy. Furthermore, 
that information would be given earlier in pregnancy. While early definitive information for all 
initially seems attractive, we suggest there are strong reasons why it might not be so good in 
practice.  
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i) Early, definitive results and informed decision-making 
Under Model One, since women would receive definitive information earlier than if they underwent 
combined screening followed by invasive testing, they may in turn feel reassured earlier if the result 
is normal, and, if abnormal, they would either have more time to plan and prepare for raising a child 
with that condition or have more time to make a decision about ending the pregnancy.  
The timing would also allow for earlier termination. For those who take a gradualist view of 
personhood and fetal rights, the moral implications of termination may be less troublesome at this 
earlier stage. For example, some religious groups regard termination as more acceptable before an 
early and specified gestational age. Earlier termination would also mean that the procedure could be 
carried out before the pregnancy became obvious to others. Evidence from women using NIPD for 
clinically indicated fetal sex determination from seven weeks gestation showed that they valued 
testing prior to the signs of pregnancy becoming obvious.[14] Further, some research shows that for 
some the termination procedure itself may be less physically and psychologically burdensome at this 
earlier stage,[15] though it should be noted that there is also evidence that this is not the case.[16]  
Despite the advantages of earlier testing, there are several downsides to consider. There is evidence 
that some women would rather delay medical testing in pregnancy because they feel overloaded 
with information in the first trimester at a time when they already undergo numerous tests, and 
would like to enjoy the ‘honeymoon’ period of the first few weeks of pregnancy and delay the onset 
of a period of worrying.[17] 
For some time, there have also been concerns that prenatal screening has become routinised, and 
that in reality the choice to undergo testing is not as informed or freely made as it could be.[18] A 
key motivation for introducing NIPD is that it will support reproductive autonomy (which we 
interpret as the power of pregnant women or couples to make free and informed decisions relating 
to reproduction, including pregnancy management). This requires that women have the opportunity 
and support to make fully informed decisions about their reproduction, rather than simply being 
allowed to make decisions without interference. We assume that reproductive autonomy can be 
expressed through informed decision-making in prenatal care and thus this is an important ethical 
discriminator between the clinical models. We do, however, recognise that fully informed decision-
making in prenatal diagnosis is difficult to achieve in practice.[19, 20] Existing psychological, social 
and institutional barriers will remain for each model of NIPD we discuss here. Even so, some models 
of care will be better than others at supporting informed decision-making. 
 
Empirical evidence indicates that an erosion of informed decision-making is a real possibility with the 
introduction of NIPD,[21] and the challenge for each model is to mitigate this as much as possible. In 
Model One (and Two, which we will come to) there would be no initial risk assessment, and 
therefore the process of undergoing testing for aneuploidy would be quicker. Since definitive results 
are derived from a single blood test, the ease of the test lends itself to routinisation. While the 
simple nature of NIPD is part of its appeal, it is disproportionate to the potential significance of the 
results. Routinely offering a test that gives definitive information at this point may mean women find 
themselves with information for which they had not been fully prepared. As Hall et al suggest in the 
context of Down syndrome screening:  
…a subsequent invasive diagnosis (as a separate test following a probabilistic result) 
currently provides another opportunity for reflection in the context of providing consent for 
that procedure (namely screening for aneuploidy). By potentially replacing the existing 
multi-step Down syndrome screening process with a single early highly predictive blood test, 
the use of cffDNA technology may reduce opportunities for exercising informed choice.[22] 
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Thus, the decision whether to undergo NIPD is arguably of greater magnitude than the decision to 
undergo combined screening. The need to build in time for reflection, deliberation, decision-making 
and thinking ‘space’[23] to ensure informed decision-making for such a simple yet momentous test 
has been emphasised elsewhere in the literature.[24, 25] 
These problems could perhaps be avoided by introducing a separate appointment to facilitate 
informed decision-making about NIPD prior to it taking place and ensuring there is appropriate 
counselling relating to the definitive nature of the results, but providing NIPD at 10 weeks leaves 
very little time for adequate counselling and reflection for such a significant test.  
ii) Loss of information 
Research has shown that combined screening can detect increased risk for other conditions, such as 
pre-eclampsia[26], intrauterine growth restriction.[27] and fetal abnormalities[28]. Because 
combined screening would not be offered under Model One, these other conditions identified by the 
screening blood test or ultrasound to measure nuchal translucency would not be detected. This 
could be addressed by modifying Model One to include screening for other conditions later in 
pregnancy, though for the reasons we outline below it would be problematic to include additional 
scanning and appointments.  
iii) Early ultrasound 
The dating scan in Model One is necessary to confirm gestation, viability and number of fetuses 
present. An earlier scan could not fully replace the usual 11-13 week scan. In addition, a scan at 
around 10 weeks would mean scanning pregnant women who may otherwise miscarry, since the 
first trimester is when pregnancy is most vulnerable to loss. The observed rate of natural miscarriage 
within the first twelve weeks of any pregnancy is 20%[29] and fetuses with chromosomal anomalies 
make up a large proportion of these spontaneous losses of pregnancy.[30]  
iv) Vulnerable pregnancy and responsibility  
 
Given the high rate of early miscarriage, Model One would present some women with difficult 
choices unnecessarily. The high rate of miscarriage in the first trimester means that offering NIPD at 
10 weeks would cause some women to face a decision about termination that they would otherwise 
not have had to make. While many of the differences between termination and spontaneous 
miscarriage relate to the process and associated medical implications, there are also important 
psychological and moral differences. With abortion, the woman has chosen to terminate her 
pregnancy; with miscarriage it has happened to her.3 Thus establishing as a standard practice the 
offer of NIPD at this early stage, when a fetus with a chromosomal aneuploidy may miscarry 
naturally, could introduce a burden of choice,[4] and responsibility that may ultimately be more 
burdensome than empowering.  
Model Two 
The most notable feature of Model Two is that all women would be offered risk-free information 
that is definitive. Compared with Model One, in Model Two NIPD would be performed later and 
would be accompanied by screening for other conditions. This would mean women would be given 
fuller information about their pregnancy. 
                                                          
3
 Even in the case of spontaneous miscarriage a woman may feel responsible, culpable and guilty, perhaps 
because of the real or perceived possibility that her own behaviour or health played a part in causing the 
miscarriage.[31] 
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Under this model, only one standard ultrasound would take place, and this would be after the most 
vulnerable stage of pregnancy had passed, so the likelihood of women making a decision about 
whether to terminate a pregnancy that would otherwise miscarry naturally would be reduced. 
As with the first model, Model Two could be subject to concerns about routinisation compromising 
informed decision-making. Although this is a problem for all prenatal screening, the ease of testing 
in NIPD could exacerbate the issue. One possible solution to this would be to impose strict 
procedures for promoting informed consent that would encourage informed decision-making as 
much as possible. This would be easier under Model Two than Model One given that testing takes 
place later, offering women more ‘thinking space’ between the first appointment with a healthcare 
professional and the delivery of NIPD. Women would have had more opportunity to think about the 
impact of abnormal findings, as long as information about NIPD was given to and discussed with 
them at an early antenatal appointment. With good counselling procedures in place women and 
couples offered NIPD under Model Two could feasibly have the time to think about whether they 
would like to receive a definitive result as to the presence of an aneuploidy. 
Model Three 
The most notable feature of Model Three is that diagnosis of aneuploidy would be offered in two 
clinical stages: a probabilistic risk analysis (combined screening as is carried out currently) followed 
by an offer of definitive NIPD for those who receive a high risk result. It differs from current practice 
by removing the risk of miscarriage associated with current invasive diagnostic tests. 
Model Three presents a step-wise process in the diagnosis of aneuploidy so that couples would first 
have the chance to reflect on a risk-based result before progressing to receive definitive information. 
This may potentially reduce the chances of women agreeing to definitive diagnosis without making a 
fully informed decision and suddenly finding themselves with information about which they had not 
given enough thought. This model could reduce the problems around informed decision-making 
discussed above and maximise the chances that women were as aware as possible of the 
implications of a definitive test.  
However, Model Three strikes us as an unnecessarily cautious approach, because instigating this 
level of prudency would require a trade-off with the lost opportunity for definitive information for 
those whose pregnancies were deemed to be low risk. Combined screening does not detect all cases 
of aneuploidy (for example the UK national benchmark detection rate for screening of Down 
syndrome is 90%).[32] When compared with Model Two, which includes time for reflection and 
offers definitive diagnosis to all pregnant women, this model that maintains a higher likelihood of 
false reassurance for one group of women.4 If reproductive autonomy is important, we would need 
good reason not to improve the chances of all pregnant women having the opportunity to receive 
definitive information about aneuploidy in pregnancy. 
COMPARING THE MODELS 
Of the models we have discussed, Model One is most different to current screening programmes 
because all women would be offered a definitive test (not just those women deemed ‘high risk’ after 
combined screening); it would be carried out earlier, it would not include an initial risk assessment, 
and it would not detect risk for as wide a range of conditions. Earlier testing has the attractions of 
reassurance or decision-making about continuing or terminating a pregnancy at an earlier 
gestational age. While this would increase choice and control for women, for many it will present an 
unnecessary burden because they will make a decision to terminate a pregnancy that would 
                                                          
4
 With thanks to Anita de Jong for the point about the problem with false reassurance in Model Three. 
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miscarry naturally. This is a significant concern, and the advantages of earlier testing are quickly 
outweighed when this is considered alongside the other draw-backs of Model One, namely the loss 
of information regarding other pregnancy complications and risk of exacerbating routinisation, and 
when compared with Model Two. 
Model Three is most closely aligned with current practice. NIPD would be offered after combined 
screening and would replace the invasive methods currently offered to pregnant women when the 
screening result indicated a high risk. One of the most compelling aspects of Model Three is its two-
stage structure. Giving women a risk result first builds in time for reflection and may be more 
conducive to ensuring women make informed decisions. However, because under Model Three NIPD 
would only be offered to those women assessed as high risk, many others would miss out on 
receiving definitive information about whether their fetus had an aneuploidy. In addition, there 
remains the possibility of women receiving falsely reassuring results at the screening stage. We 
therefore regard it as a mistake to include a risk assessment purely as an intermediary stage if good 
counselling could serve the purpose of preparing woman and couples for making an informed 
decision about definitive testing, as we believe could occur under Model Two. If reproductive 
autonomy is important (and it seems reasonable to suggest that it is), then we would need good 
reason not to maximise the chances to achieve it for all pregnant women by offering Model Two.  
Model Two would bring forward the time at which women would receive a definitive result, but 
testing would not be carried out at the most vulnerable period of pregnancy when many women 
would find themselves faced with an unnecessary burden of choice. Under Model Two all women 
would be offered definitive testing through NIPD. This would mean offering reassurance to all 
women whose fetuses did not have an aneuploidy. It would also mean that those women whose 
fetuses have an aneuploidy (but who would have been deemed ‘low risk’ with combined screening) 
could receive a definitive positive result. 
There is, however, a remaining concern that, unless it is implemented with careful thought for the 
decision-making process, adopting Model Two may see a routinisation of NIPD and a loss of ‘thinking 
space’ for women to consider whether they would like to receive definitive information. 
Mechanisms would need to be in place to ensure that women were fully aware of the nature of the 
conditions covered by the testing process and that they had enough time to reflect on the offer of 
the test and how it sat with their own values. The most obvious ways to do this would be to increase 
counselling provision, to provide clear and helpful information, and to ensure that women were 
given sufficient time between being offered the test and accepting it. The nature of counselling 
would have to change with the move to definitive information; women and couples would need to 
think more about the condition rather than the nature of probabilities that the test will give rise to.  
CONCLUSION 
If it does become possible to use NIPD from as early as 10 weeks gestation for aneuploidy detection 
with an accuracy of 100%, policy-makers will have to consider whether and how best to implement 
it. Ultimately, implementation will depend on the clinical possibilities and will necessitate balancing 
the practicalities of antenatal screening programmes, financial constraints and ethical 
considerations. Our reasons for favouring Model Two (offering NIPD with combined screening to 
replace current combined screening and follow-up testing) are that it gives choice to the greatest 
number of women, without introducing problems associated with very early testing and loss of 
potential benefits of combined screening. This would allow each pregnant woman the opportunity 
to find out whether her baby has one of the major trisomies. To safeguard against routinisation and 
erosion of informed decision-making Model Two would need to be underpinned with sound 
counselling and time for reflection.  
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As well as a comprehensive analysis of the necessary resources to implement Model Two, what is 
currently missing from this discussion is an indication of the preferences of pregnant women and 
couples. As an interim measure and to inform future practice, it may be worth offering women the 
choice between combined screening and NIPD (Model Two) and combined screening with follow-up 
NIPD for high-risk pregnancies (Model Three) and audit the choices they make. 
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